1P

Dechra Pharmaceuticals PLCFRA Dechra Pharmaceuticals Stock Report

Last reporting period 30 Jun, 2023

Updated —

Last price

Market cap $B

5.886

Middle

Exchange

XFRA - Deutsche Boerse AG

1PK.F Stock Analysis

1P

Uncovered

Dechra Pharmaceuticals PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

14/100

Low score

Market cap $B

5.886

Dividend yield

Shares outstanding

113.85 B

Dechra Pharmaceuticals PLC is a holding company, which engages in the veterinary pharmaceuticals and related products business. The company is headquartered in Northwich, Cheshire and currently employs 2,036 full-time employees. The company went IPO on 2000-09-21. The Company’s segments include European Pharmaceuticals, NA Pharmaceuticals, and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment comprises of Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing & Supply. This Segment operates internationally and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Dechra Veterinary Products Canada, and Dechra Productos Veterinarios (Mexico), which sell CAP, Equine and FAP in those territories. The Segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas. The Pharmaceuticals Research and Development Segment includes all of the Company's pharmaceutical research and development activities.

View Section: Eyestock Rating